MedPath

Elranatamab

Generic Name
Elranatamab
Brand Names
Elrexfio
Drug Type
Biotech
Chemical Formula
-
CAS Number
2408850-14-4
Unique Ingredient Identifier
L0HR9A577V
Background

Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure. The resulting 4-chain bispecific antibody is covalently linked via five inter-chain disulfide bonds. On August 14, 2023, the FDA granted accelerated approval to elranatamab for the treatment of multiple myeloma.

Indication

Elranatamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

Associated Conditions
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Associated Therapies
-
Clinical Trials
Related News
openpr.com
·

Cytokine Release Syndrome Treatment Market 2034: Clinical

The Cytokine Release Syndrome market is expected to surge due to increasing disease prevalence and awareness, with multiple-stage pipeline products revolutionizing market dynamics. The market report covers epidemiology, emerging drugs, current treatment practices, and market size from 2020 to 2034 in the United States, EU5, and Japan. Key companies and therapies include Swedish Orphan Biovitrum, Incyte, Kite (Gilead), Jazz Pharmaceuticals, and therapies like KINERET (anakinra) and Itacitinib. Market drivers include increasing incidence and R&D activities, while barriers include lack of awareness and misdiagnosis.
pharmacytimes.com
·

Immunotherapy Evolution Continues with Innovative Approaches to Multiple Myeloma Treatment

Immunomodulatory agents, monoclonal antibodies, bispecific antibodies, and CAR T-cell therapy have transformed multiple myeloma treatment. Despite improvements, MM remains incurable, prompting research into protein degradation and immune system activation. The triSpecific antibody JNJ-79635322 targets BCMA, GPRC5D, and CD3, showing promise in preclinical trials. Other approaches include BCMA-targeting ADCs like belantamab mafodotin and small molecule E3 ligase modulators like mezigdomide, aiming to enhance immunotherapies and prolong patient survival.

Related Clinical Trials:

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
globenewswire.com
·

Global Bispecific Antibodies Clinical Trials Market Size

Bispecific antibodies market highlights include >30 development platforms, >USD 8B market size in 2023, and >800 clinical trials. Key approved antibodies like Blincyto and Hemlibra have seen significant sales. The market is driven by innovations in immuno-oncology, with ongoing trials by major pharma companies and research institutions globally.
labiotech.eu
·

Two targets, one solution: The rise of bispecific antibodies

Bispecific antibodies, with two binding domains, offer targeted therapeutics and address co-administration challenges, gaining traction in biopharma. Initially approved for cancer, they now target various diseases, with 12 approved in the U.S. and more in development. Their dual action reduces patient burden and enhances treatment effects, potentially transforming therapeutic paradigms beyond oncology. The market is projected to grow significantly due to rising chronic disease incidence and technological advancements.
nature.com
·

Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed

Multiple studies report on survival outcomes and therapies for multiple myeloma, including retrospective analyses, phase trials, and real-world data, highlighting advancements in treatment strategies and overall survival improvements.
news.stv.tv
·

Man with incurable cancer among first to undergo ground-breaking new treatment

NHS approves groundbreaking myeloma drugs elranatamab and teclistamab for patients who have received three or more treatments. These bispecific antibodies, the first new class of myeloma drugs in nearly seven years in Scotland, can halt the disease for at least 11 months and induce complete remission in some previously non-responders.
finance.yahoo.com
·

Pfizer (PFE) Q1 2024 Earnings Call Transcript

Pfizer's Q1 2024 earnings call highlighted a solid start to the year, with a focus on executing five strategic priorities: achieving world-class oncology leadership, delivering pipeline innovation, maximizing new product performance, expanding margins, and enhancing shareholder value. The company reported operational revenue growth of 11% excluding COVID products, with notable progress in oncology and other key areas. Pfizer also discussed its cautious optimism for the year ahead, emphasizing disciplined execution and strategic investments to drive growth and shareholder returns.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy